PATENT CLAIM ANALYSIS

Application Number: 15893804
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "264110"]

Abstract:
A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof

Claim (Index 36):
The method of  claim 35 , wherein the prostate cancer is at least one selected from the group consisting of castration resistant prostate cancer, hormone resistant prostate cancer, PSA recurrent prostate cancer, taxan resistant prostate cancer, and radiation resistant prostate cancer.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 88.0
- Lexical Diversity: 2.09375
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15203059', '15023894', '15771487', '13391895', '14923525']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.837237983223585
- 35 USC 102 Novelty (BERT): 0.617658790316482
- Combined Prediction Score: 0.8152800639328748
- Mean Citation Score: 506.41254799999984
- Max Citation Score: 695.1665
- Similarity Product: 469.7524347300232

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test